samedan logo

home > news > detailed info

H&T Presspart unveil low GWP propellant filling facility

H&T Presspart

Blackburn, UK- 22nd June 2022 Ė
H&T Presspartís Inhalation Product Technology Centre (IPTC) is pleased to announce the opening of our laboratory facility to support the development of sustainable metered-dose inhalers with low global warming potential (GWP) propellant.

The new facility has the ability to fill metered-dose inhalers with a range of formulations with both HFA 152a and HFO1234ze low GWP propellants, to support our customersí development programmes of next generation low GWP metered-dose inhalers.

With a 25 litre mixing vessel, single stage filling with single or dual fill capability, H&T Presspartís IPTC can now produce batch sizes up to 2000 cans for in vitro testing.

Complementarily, IPTC can support customers with product development, analytical services and product transfers to the new propellants for both, solution and suspension type formulations and can advise on pMDI component selection including canister, actuator configurations and suitable valve types.

Ameet Sule, Director of H&T Presspartís IPTC commented, "This new facility will be crucial in supporting our customers to lower the environmental footprint and future proof inhalation products as they look to move towards more sustainable low GWP propellants for both current and new pMDI formulations. It complements the range of other inhalation testing services we already offerí.

For more information on H&T Presspartís Inhalation Product Technology Centre, as well products and services we offer please visit:
phone +44 1254 582233
email Presspart Manufacturing Ltd. Whitebirk Industrial Estate Blackburn, Lancashire BB1 5RF, England
Print this page
Send to a friend
News and Press Releases

Sharp Adds New Talent in Global Operations and Finance to Senior Leadership Team

Sharp, a leading provider of pharmaceutical packaging and clinical services, has appointed Michael Moes as Senior Vice President, Global Operations and Roger Sim as SVP & Chief Financial Officer.
More info >>

White Papers

Backward Thinking

Development of a generic equivalent to a current marketed pressurized metered dose inhaler (pMDI) product brings immense challenges. Thorough analysis is critical to gain a comprehensive understanding of the physical attributes and pharmaceutical performance of the reference marketed product. Many factors need to be assessed, understood and combined in order to successfully develop a generic pMDI which will meet the regulatory and quality requirements as an equivalent product in the anticipated target market.
More info >>

Industry Events

Connect in Pharma

14-15 September 2022, Plaexpo, Geneva, Switzerland

The new event driving innovation for pharma and biopharma businesses, Connect in Pharma will unite key players in Pharmaceutical and Biopharmaceutical packaging and production in Geneva on 14 Ė 15 September 2022.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement